Argenx stock at EUR 724.80, market value USD 50.7 billion

Published on 10/09/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock was EUR 724.80 on October 9, 2026, versus EUR 729.90. Goldman Sachs set a EUR 982.00 target on September 25, 2026.

Key points in brief

Argenx stock was EUR 724.80 at Lang & Schwarz on October 9, 2026, down 0.70 percent versus EUR 729.90.
The company had a USD 50.7 billion market capitalization and a P/E ratio of 31.23 on October 9, 2026.
Goldman Sachs raised its Argenx target from EUR 973.00 to EUR 982.00 on September 25, 2026.
The next reported earnings date is October 22, 2026.

Architekturaufnahme eines modernen Biotechnologie-Campus in Belgien, Glas-Stahl-Gebäude mit Dachgärten, Radfahrer auf baumgesäumter Allee, nordeeuropäischer Himmel — Argenx NL0010832176 moderner belgischer Biotech-Campus mit Glasfassaden und Radfahrern unter bewölktem Herbsthimmel, Illustration mit AI erstellt.

At 4:05 p.m. CEST on October 9, 2026, argenx stock was trading at EUR 724.80 at Lang & Schwarz, down 0.70 percent versus the prior close of EUR 729.90. The quote places the company below its recent market value of USD 50.7 billion and a P/E ratio of 31.23.

Price and valuation

The USD quote for argenx was USD 815.04 at 10:11 a.m. ET on October 9, 2026, down 0.44 percent on the day. Its 52-week range was USD 661.85 to USD 1,072.75, while trading volume stood at 82,006 shares against an average volume of 317,264 shares.

The latest market figures put argenx at USD 50.7 billion in market capitalization and a P/E ratio of 31.23 on October 9, 2026. The company paid no dividend according to the quoted figures, which listed a dividend yield of 0.00 percent.

Target and earnings date

Finanznachrichten reported on September 25, 2026, that Goldman Sachs raised its target for argenx from EUR 973.00 to EUR 982.00 and kept a Buy rating. The target is EUR 257.20 above the Lang & Schwarz price, but the currencies and venues differ, so no percentage distance is applied.

According to JrHisse, argenx is scheduled to report its next earnings on October 22, 2026. The latest reported second-quarter figures listed revenue of USD 1.54 billion and earnings per share of USD 7.32 against consensus of USD 1.43 billion and USD 6.19, respectively.

Comparison with peers

argenx: minus 0.70 percent, P/E 31.23, market capitalization USD 50.7 billion (October 9, 2026)
Vertex Pharmaceuticals (NASDAQ, USD): plus 2.28 percent, P/E 29.93, market capitalization USD 130.6 billion (October 9, 2026)
UCB (Euronext Brussels, EUR): plus 0.94 percent, P/E 17.64, market capitalization EUR 38.8 billion (October 9, 2026)

Clinical setback remains dated context

On October 8, 2026, Finanznachrichten carried argenx's update that the Phase 3 UNITY study of efgartigimod in Sjogren's disease would be discontinued after an interim review found the study unable to meet its primary endpoint.

Trading context

argenx is listed on Euronext Brussels under ticker ARGX.BR, with Health Care and Biotechnology classifications. The company was valued at EUR 724.80 at Lang & Schwarz on October 9, 2026 at 4:05 p.m. CEST, compared with the EUR 729.90 prior close.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.